AcquisitionsApr 15, 2026, 07:02 AM
Stereotaxis to Acquire Robocath, Expanding Robotic Endovascular Platform
AI Summary
Stereotaxis, Inc. has entered into a definitive agreement to acquire Robocath, a venture-backed innovator of robotic technologies for interventional cardiology and neurointerventions. This acquisition aims to strengthen Stereotaxis' position in endovascular procedures by combining complementary robotic technologies. The deal is expected to contribute approximately $2 million in annual revenue during the first year post-acquisition and become breakeven by the third year.
Key Highlights
- Stereotaxis to acquire Robocath, a robotic technology innovator.
- Robocath's R-One+ system is commercially available in Europe with 15 installations.
- Robocath is developing a next-gen system for up to five interventional devices.
- Acquisition expected to contribute $2 million in annual revenue in the first year.
- Acquisition projected to become breakeven by the third year.